Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Wolbachia Mosquito Study Shows 68.5% Reduction in Dengue Infections Among Children

Wolbachia Mosquito Study Shows 68.5% Reduction in Dengue Infections Among Children

November 22, 2026 Health Desk Health

Children living in neighborhoods treated with modified mosquitoes saw a 68.5 percent drop in dengue cases, according to a clinical trial involving 5,757 participants that was presented at the American Society of Tropical Medicine and Hygiene congress in the United States.

Key Clinical Takeaways:

  • A clinical trial following 5,757 children aged 6 to 11 found that introducing mosquitoes carrying the Wolbachia bacteria reduced overall arbovirus infections by 68.6 percent between 2020 and 2024.
  • Protection rates remained steady during Brazil’s largest historical dengue epidemic in 2024, with specific drops of 68.5 percent for dengue and 73.3 percent for chikungunya.
  • Municipal authorities in Itajaí announced plans to begin releasing the bacteria-carrying mosquitoes in December, following unanimous commercial authorization from Anvisa.

The trial tracked children across 58 areas in Belo Horizonte, Minas Gerais, between 2020 and 2024, as reported by Diário da Região. Researchers compared infection rates in regions receiving mosquitoes infected with Wolbachia against control areas.

For dengue, the reduction reached 68.5 percent, while chikungunya infections fell by 73.3 percent, according to Diário da Região. Overall arbovirus infections decreased by 68.6 percent among children aged 6 to 11.

“That is really exciting,” Dr. David Hamer, a global health specialist at Boston University who did not participate in the research, told Tribuna do Agreste.

Hamer said that combining this vector strategy with current interventions could reduce dengue to much lower levels in heavily impacted regions. Dr. Sri Edupuganti of Emory University said that the protective effect held firm throughout 2024, when Brazil faced its largest dengue epidemic on record.

Wolbachia Mosquito Study Shows 68.5% Reduction in Dengue Infections Among Children
Photo: Diário da Região

Funding and Research Collaboration Behind the Trial

The study protocol appeared in the journal Trials in 2022, and the trial is registered on ClinicalTrials.gov under the identifier NCT04514107, Dhoje Interior reported.

Mauricio Nogueira Lacerda of Famerp played a fundamental role in the study, according to Diário da Região. Luciano Moreira of Fiocruz and the World Mosquito Program in Brazil said that the research team successfully maintained the bacteria within the local mosquito population for over three years.

“We are pleased that we developed this strain and that we achieved and sustained the level of mosquitoes infected with Wolbachia for more than three years,” Moreira told Dhoje Interior.

Commercial Authorization and Municipal Rollout in Itajaí

Following these clinical findings, the Brazilian Health Regulatory Agency granted unanimous authorization for the commercialization of the Wolbachia method to states and municipalities, according to Portal Comunique-se. Wolbito do Brasil serves as the exclusive organization authorized to implement the methodology in the country in partnership with the World Mosquito Program, Portal Comunique-se reported, according to Globo.

Anvisa autoriza comercialização do Método Wolbachia
Photo: Portal Comunique-se

“We have a list of dozens of municipalities that have been contacting us since the inauguration of the biofactory with interest in receiving the method in their territory,” Gabriel Sylvestre, implementation manager for Wolbito do Brasil, told Portal Comunique-se. “With this authorization, we can reach more municipalities, with all the quality that was built so far with Fiocruz and the Ministry of Health.”

Cities slated to receive the intervention include Ribeirão Preto, Araraquara, and São José do Rio Preto in São Paulo; Contagem in Minas Gerais; Foz do Iguacu and Cascavel in Paraná; Anápolis, Aparecida de Goiânia, and Trindade in Goiás; Olinda in Pernambuco; and Rio Branco in Acre, according to Portal Comunique-se.

The complete results from the Belo Horizonte trial remain preliminary and await peer review before publication in a scientific journal, according to Diário da Região.

Belo Horizonte, the capital of Minas Gerais, holds the distinction of being the first planned modern city in Brazil. Originally established as a village in 1701, the site was later selected in 1893 to replace Ouro Preto as the state capital, with urban planners drawing inspiration from the layout of Washington, D.C. Today, it ranks as the sixth-most-populous city in the country, with a population of approximately 2.4 million people.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Keep reading

  • CONICET Researcher Analyzes Ethics of Genetic Screening for Donors
  • Tonali Misses Tottenham Squad Through Illness as Udogie Returns to Starting XI
  • Rebel Wilson Shows 80-Pound Weight Loss in Sydney After Semaglutide Disclosure (archyde.com)

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service